Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia.
chronic myeloid leukemia
imatinib
regulatory T cells
treatment-free remission
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Nov 2021
24 Nov 2021
Historique:
received:
03
10
2021
revised:
02
11
2021
accepted:
15
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Treatment-free remission (TFR) has become a therapeutic goal in chronic myeloid leukemia (CML), and approximately half of the patients with chronic phase-CML (CML-CP) with deep molecular remission (DMR) by tyrosine-kinase inhibitors (TKIs) have achieved TFR. However, the mechanism of continuous TFR is still unclear, as there are "fluctuate" patients who have BCR-ABL-positive leukemia cells but do not observe obvious relapse. We focused on the immune response and conducted an immune analysis using clinical samples from the imatinib discontinuation study, JALSG-STIM213. The results showed that, in the group that maintained TFR for 3 years, changes in regulatory T (Treg) cells were observed early after stopping imatinib treatment. The effector Treg (eTreg) cells increased transiently at 1 month after stopping imatinib and then returned to baseline at 3 months after stopping imatinib treatment. There was no difference in the Treg phenotype, and CD8
Identifiants
pubmed: 34885012
pii: cancers13235904
doi: 10.3390/cancers13235904
pmc: PMC8657169
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 15ck0106189h0001
Organisme : Japan Agency for Medical Research and Development
ID : 16ck0106189h0002
Organisme : Japan Agency for Medical Research and Development
ID : 17ck0106189h0003
Références
Eur J Immunol. 2019 Aug;49(8):1140-1146
pubmed: 31257581
Blood Adv. 2019 Jul 9;3(13):2022-2034
pubmed: 31289029
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Nat Commun. 2019 Nov 28;10(1):5415
pubmed: 31780669
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
N Engl J Med. 2003 Mar 13;348(11):994-1004
pubmed: 12637609
Int Immunol. 2016 Aug;28(8):401-9
pubmed: 27160722
J Exp Med. 2020 Feb 3;217(2):
pubmed: 31704808
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196
Clin Cancer Res. 2019 Aug 1;25(15):4808-4819
pubmed: 31076547
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
Int J Hematol. 2018 Feb;107(2):185-193
pubmed: 28929332
Haematologica. 2017 Aug;102(8):1368-1377
pubmed: 28522576
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Int J Hematol. 2008 Nov;88(4):409-417
pubmed: 18953513
Blood. 2011 Aug 25;118(8):2035-43
pubmed: 21693757
Nat Immunol. 2020 Nov;21(11):1346-1358
pubmed: 32868929
Blood. 2005 Mar 15;105(6):2473-9
pubmed: 15572591
Leuk Res. 2011 May;35(5):585-90
pubmed: 21145591
Leukemia. 2005 Nov;19(11):1905-11
pubmed: 16151467
J Clin Oncol. 2014 Feb 10;32(5):424-30
pubmed: 24323036
Blood Adv. 2019 May 28;3(10):1610-1621
pubmed: 31126916
Br J Haematol. 2020 Nov;191(3):433-441
pubmed: 32352166
Leukemia. 2017 Apr;31(4):829-836
pubmed: 28074067
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
J Chromatogr Sci. 2011 May;49(5):412-5
pubmed: 21549035
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Leukemia. 2017 May;31(5):1108-1116
pubmed: 27890936
Br J Haematol. 2019 Jul;186(1):54-59
pubmed: 30864168
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1
pubmed: 29610029
Blood. 2013 Jul 11;122(2):227-38
pubmed: 23719297
Curr Opin Immunol. 2014 Apr;27:1-7
pubmed: 24413387
Lancet Haematol. 2015 Dec;2(12):e528-35
pubmed: 26686407
Int Immunol. 2018 Feb 3;30(1):13-22
pubmed: 29294043
Leukemia. 2021 May;35(5):1229-1242
pubmed: 33833387
Blood. 2017 Mar 2;129(9):1166-1176
pubmed: 28049640
J Exp Med. 2007 Aug 6;204(8):1757-64
pubmed: 17620361
Ann N Y Acad Sci. 2018 Apr;1417(1):104-115
pubmed: 29566262
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299